Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study
Bas W.G. van Rhijn(The Netherlands Cancer Institute), Tahlita C.M. Zuiverloon(Erasmus MC), Y. Neuzillet(Université de Versailles Saint-Quentin-en-Yvelines), Cheno Abas(Erasmus MC), Michiel S. van der Heijden(Zorginstituut Nederland), Yanish Soorojebally(Université de Versailles Saint-Quentin-en-Yvelines), Ellen C. Zwarthoff(Erasmus MC), Yair Lotan(Southwestern Medical Center), Roman Mayr(Ospedale di Bolzano), Theodorus van der Kwast(Erasmus MC), Nanour Sirab(Centre National de la Recherche Scientifique), A. Hartmann, Shahrokh F. Shariat(Universitätszahnklinik Wien), Joost L. Boormans(Erasmus MC), Markus Eckstein(Friedrich-Alexander-Universität Erlangen-Nürnberg), François Radvanyi(Centre National de la Recherche Scientifique), Peter J. Boström(University of Turku), Yves Allory(Institut Curie), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Geert van Leenders, Max M. Burger(Radboud University Nijmegen), Laura S. Mertens(Oncode Institute), Michael Jewett(Cancer Genomics Centre), Alexandre R. Zlotta(University of Toronto)
Cited by 0
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k